Morepen Laboratories Ltd. — Capital/Financing Update 2024

Dec 27, 2024

==> picture [92 x 841] intentionally omitted <==

==> picture [80 x 73] intentionally omitted <==

==> picture [159 x 37] intentionally omitted <==

Date: 27/12/2024

To,

National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Symbol: MOREPENLAB Scrip Code: 500288

Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations”) read with Para A, Part A, Schedule III of the SEBI LODR Regulations

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI LODR Regulations read with Para A, Part A, Schedule III of the SEBI LODR Regulations, 2015, as amended , we would like to inform that the company is incorporating a new subsidiary company by subscribing and acquiring 80% Equity Shares of the said new subsidiary company.

The necessary disclosures pursuant to SEBI Circular no. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, is enclosed herewith as Annexure.

Yours faithfully,

For Morepen Laboratories Limited

Vipul Digitally signed by Vipul Kumar Kumar Srivastava Srivastava Date: 2024.12.27 19:41:18 +05'30' Vipul Kumar Srivastava Company Secretary F-12148 Encl.: a/a.

Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com

==> picture [92 x 841] intentionally omitted <==

==> picture [80 x 73] intentionally omitted <==

==> picture [159 x 37] intentionally omitted <==

Annexure

Disclosure under Regulations 30 of the LODR read with Para A, Part A, Schedule III of the LODR and the circular no. SEBI/ HO/ CFD/ CFD-PoD-1/ P/ CIR/ 2023/ 123 issued by SEBI dated July 13, 2023.

==> picture [433 x 535] intentionally omitted <==

----- Start of picture text -----

Sr. Particulars Details
a) name of the target entity, details in brief The proposed new subsidiary company,
such as size, turnover etc.; being target entity, is under incorporation
therefore name will be intimated in due
course.
The proposed authorised & paid up capital
will be ₹10,00,000/- (Rupees Ten Lakh
Only) divided into 1,00,000 (One Lakh)
Equity Shares of ₹ 10/- (Rupees Ten) each.
Size, Net Worth & Turnover - Not
applicable.
b) whether the acquisition would fall The proposed new subsidiary will be formed
within related party transaction(s) and in the capital ratio of (80:20) i.e., 80%
whether the promoter/ promoter group/ equity shares will be subscribed and held by
group companies have any interest in the Company and remaining 20% by the
the entity being acquired? If yes, nature promoter, members belonging to promoter
of interest and details thereof and & promoter group and relatives thereof.
whether the same is done at “arm’s
length”;
c) industry to which the entity being The proposed new company will be engaged
acquired belongs; in the business of medical devices.
d) objects and impact of acquisition The objective of incorporation of new
(including but not limited to, disclosure subsidiary is to enhance the capabilities,
of reasons for acquisition of target expansion of business operations and
entity, if its business is outside the main strategic alignment.
line of business of the listed entity);
e) brief details of any governmental or Not applicable
regulatory approvals required for the
acquisition;
f) indicative time period for completion of Not applicable
the acquisition;
g) consideration - whether cash Cash
consideration or share swap or any
other form and details of the same;
----- End of picture text -----

Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com

==> picture [92 x 841] intentionally omitted <==

==> picture [80 x 73] intentionally omitted <==

==> picture [159 x 37] intentionally omitted <==

h)	cost of acquisition and/or the price at which the shares are acquired;	The Company will subscribe 80,000 (Eighty Thousand) Equity Shares of ₹ 10/- (Rupees Ten) each, aggregating to ₹ 8,00,000/- (Rupees Eight Lakh Only) of proposed new subsidiary.
i)	percentage of shareholding / control acquired and / or number of shares acquired;	The company will hold 80% shares in the proposed new subsidiary.
j)	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	The proposed new subsidiary will be engaged in the business of medical devices.

Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com